#Viekira Pak

Human rights activist Philip Baldwin writes about his experiences living with hepatitis C and HIV, and his treatment for hep C.

Researchers identified this association after looking at real-world data on a large group of German individuals with HIV and hep C.

A large study shows that hepatitis C treatment is associated with increased mortality.

A promising new regimen that will address unmet needs for this population is poised for FDA approval.

Those who beat hep C also reduced their insulin use.

The triple-drug regimen comes in a once-daily single tablet.

A recent economic analysis sheds light on whether averting hep C–driven severe liver disease through treatment is worth the expense.

The antiviral drug, which for some people can be a beneficial adjunct to the new crop of hep C medications, has gotten a bad rap.

Part 2 of Connie Welch’s interview with a hep C patient sharing her experience with hepatitis C treatment.

Hep C patient Denise shares her story about being cured with cured using Viekira Pak

FDA warns of risk of hepatitis B virus reactivation in patients coinfected with hepatitis C virus and hepatitis B virus.

This Hep story shows the power of never giving up, and the transformation that comes as a result.

The standard treatment duration is 12 or 24 weeks.

It’s a year since I took my last lot of tablets. A whole year.

AbbVie has applied for approval from the FDA for a new formulation of Viekira Pak that only needs to be taken once a day